Clinical Trial Update: Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Migraine [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is investigating botulinum toxin type A blockade of the sphenopalatine ganglion for treatment-refractory chronic migraine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• OnabotulinumtoxinA (botulinum toxin type A)

Snippet

Sponsor: St. Olavs Hospital | Conditions: Migraine Disorders | Phase 3 | Status: ACTIVE_NOT_RECRUITING